TRIUMPH-1: What 28.3% Actually Means
Lilly published the number everyone is sharing. The result is big. The catch is simple: the drug's still investigational and Australia has no pharmacy product today.
Direct answer
Lilly reported that the 12 mg retatrutide arm in TRIUMPH-1 lost an average of 70.3 lb, or 28.3%, at 80 weeks. Retatrutide is still investigational and isn't an approved Australian medicine today.
Reviewed for
Lilly TRIUMPH-1 topline release
Australian approval status boundary
Buyer-path language
Published 23 May 2026. Medical reviewer pending. No clinician credential is claimed.
What 28.3% actually means
Direct answer
The headline result is 28.3% average body-weight reduction at 80 weeks in Lilly's reported 12 mg arm.
Lilly reported that TRIUMPH-1 participants taking 12 mg retatrutide lost an average of 70.3 lb, or 28.3% of body weight, over 80 weeks.
That's why retatrutide is getting attention. It isn't another small GLP-1 headline. It's the reason Australians are searching before the medicine is here.
12 mg arm: 70.3 lb average reduction at 80 weeks
9 mg arm: 64.4 lb average reduction at 80 weeks
4 mg arm: 47.2 lb average reduction at 80 weeks
45.3% of 12 mg participants achieved at least 30% body-weight reduction
Why this isn't another Mounjaro
Direct answer
Retatrutide is a triple agonist. Mounjaro acts on GLP-1 and GIP; Ozempic acts on GLP-1.
Mounjaro hits two receptors. Ozempic hits one. Retatrutide hits three - GLP-1, GIP, and glucagon.
That's not a tweak. That's the next generation, and it's why the safety profile and tolerability details matter, not just the weight-loss number.
What the data doesn't prove
Direct answer
The result doesn't make retatrutide approved in Australia and doesn't replace clinical advice.
It doesn't mean retatrutide is approved in Australia. It doesn't mean a doctor can prescribe a finished retatrutide medicine today. It doesn't mean a lab vial is a replacement for clinical care.
It means the Phase 3 data is strong enough that Australian readers are asking a sharper question: who shows the batch, and who only shows a label?
Research peptides are not approved by the TGA for human use. Supplier links are for seller checks and buyer-protection review, not medical advice.
How we reviewed this article
This article was checked against primary source material, regulator pages, and the supplier-proof boundary used across this site. The goal is to keep triumph-1: what 28.3% actually means useful without turning it into medical advice or a fake clinical recommendation.
Checked points
Lilly TRIUMPH-1 topline release
Australian approval status boundary
Buyer-path language